Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008;12(1):R4.
doi: 10.1186/cc6765. Epub 2008 Jan 15.

Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial

Affiliations
Clinical Trial

Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial

Andreas Umgelter et al. Crit Care. 2008.

Abstract

Introduction: Circulatory dysfunction in cirrhotic patients may cause a specific kind of functional renal failure termed hepato-renal syndrome (HRS). It contributes to the high incidence of renal failure in cirrhotic intensive care unit (ICU) patients. Fluid therapy may aggravate renal failure by increasing ascites and intra-abdominal pressure (IAP). This study investigates the short-term effects of paracentesis on haemodynamics and kidney function in volume resuscitated patients with HRS.

Methods: Nineteen consecutive cirrhotic patients with HRS were studied. Circulatory parameters and renal function were analysed before and after plasma expansion and paracentesis. Haemodynamic monitoring was performed by transpulmonary thermodilution.

Results: After infusion of 200 ml of 20% human albumin solution, mean arterial pressure (MAP) and central venous pressure remained unchanged. Global end-diastolic volume index (GEDVI) increased from 791 ml m(-2) (693 to 862) (median and 25th to 75th percentile) to 844 ml m(-2) (751 to 933). Cardiac index (CI) increased from 4.1 l min(-1) m(-2) (3.6 to 5.0) to 4.7 l min(-1) m(-2) (4.0 to 5.8), whereas systemic vascular resistance index (SVRI) decreased from 1,422 dyn s cm(-5) m(-2) (1,081 to 1,772) to 1,171 dyn s cm(-5) m(-2) (893 to 1,705). Creatinine clearance (CC) and fractional excretion of sodium (FeNa) were not affected. During paracentesis, IAP decreased from 22 mmHg (18 to 24) to 9 mmHg (8 to 12). MAP decreased from 81 mmHg (74 to 100) to 80 mmHg (71 to 89), and CI increased from 4.1 l min(-1) m(-2) (3.2 to 4.3) to 4.2 l min(-1) m(-2) (3.6 to 4.7), whereas SVRI decreased from 1,639 dyn s cm(-5) m(-2) (1,168 to 2,037) to 1,301 dyn s cm(-5) m(-2) (1,124 to 1,751). CC during the 12-hour interval after paracentesis was significantly higher than during the 12 hours before (33 ml min(-1) (16 to 50) compared with 23 ml min(-1) (12 to 49)). CC remained elevated for the rest of the observation period. FeNa increased after paracentesis but returned to baseline levels after 24 hours.

Conclusion: Paracentesis with parameter-guided fluid substitution and maintenance of central blood volume may improve renal function and is safe in the treatment of ICU patients with hepato-renal failure.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow-chart of the protocol. GEDVI, global end-diastolic volume index; HA, human albumin; IAP, intra-abdominal pressure.
Figure 2
Figure 2
Creatinine clearance before and after paracentesis. The 25th, 50th and 75th centiles are given.
Figure 3
Figure 3
Fractional excretion of sodium before and after paracentesis. FeNa, fractional excretion of sodium. The 25th, 50th and 75th centiles are given.
Figure 4
Figure 4
Serum creatinine levels before and after paracentesis. Absolute values for all patients before paracentesis and at 48 hours, 7 days and 12 days after the last paracentesis are presented.

Comment in

References

    1. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151–1157. doi: 10.1002/hep.1840080532. - DOI - PubMed
    1. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Definition, diagnosis and treatment of hepatorenal syndrome in cirrhosis. A consensus workshop of the international ascites club. Gut. 2007;56:1310–1318. doi: 10.1136/gut.2006.107789. - DOI - PMC - PubMed
    1. Cheyron D, Bouchet B, Parienti JJ, Ramakers M, Charbonneau P. The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis. Intensive Care Med. 2005;31:1693–1699. doi: 10.1007/s00134-005-2842-7. - DOI - PubMed
    1. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology. 2003;37:233–243. doi: 10.1053/jhep.2003.50084. - DOI - PubMed
    1. Malbrain ML. Abdominal pressure in the critically ill: measurement and clinical relevance. Intensive Care Med. 1999;25:1453–1458. doi: 10.1007/s001340051098. - DOI - PubMed

Publication types